PEAK6
SRPT icon

PEAK6’s Sarepta Therapeutics SRPT Stock Holding History

PEAK6’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,400
Closed -$263K – 3445
2025
Q2 		$263K Sell
15,400
-87,000
-85% -$3.71M ﹤0.01% 2361
2025
Q1 		$6.54M Buy
102,400
+85,800
+517% +$9.03M 0.01% 772
2024
Q4 		$2.02M Buy
+16,600
New +$2.03M ﹤0.01% 1409

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PEAK6's SRPT Position: Q1 2026 in Review

PEAK6 reduced its Sarepta Therapeutics (SRPT) stake by 23% in Q1 2026, selling an estimated $96.8K and leaving 16,315 shares worth $355K. The position accounts for ﹤0.01% of the portfolio, ranked #2104.

PEAK6 first reported a position in SRPT in Q1 2025 and has held it in 5 quarters since. The position peaked at $2.07M in Q1 2025. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • PEAK6 held 16,315 shares of Sarepta Therapeutics worth $355K as of Q1 2026.
  • PEAK6 sold 5,000 Sarepta Therapeutics shares in Q1 2026, an estimated $96.8K.
  • Sarepta Therapeutics made up ﹤0.01% of PEAK6's portfolio in Q1 2026, its #2104 holding.
  • PEAK6 first reported a position in Sarepta Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • PEAK6's Sarepta Therapeutics position peaked at $2.07M in Q1 2025.
  • 339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on PEAK6's 13F filing for Q1 2026, filed 14 May 2026.